利妥昔单抗治疗 EBV 阳性低级别 B 细胞淋巴瘤。

Rituximab in the treatment of EBV-positive low grade B-cell lymphoma.

机构信息

Hematology Unit, First Department of Internal Medicine Laikon General Hospital, National and Kapodistrian University of Athens, Athens 11527, Greece.

出版信息

Anticancer Res. 2013 Dec;33(12):5693-8.

PMID:24324119

Abstract

BACKGROUND

Following infection of B lymphocytes by Epstein Barr virus (EBV), the viral genome remains in the nucleus, and a latency phase is established, during which only a small proportion of the viral genes are expressed. Among them, LMP1 is essential for transformation. Rituximab is a potent agent used in the treatment of low grade B-cell lymphomas and is also widely used for the treatment of post-transplant lymphoproliferative disorders caused by EBV. The effect of rituximab treatment on the latent EBV infection in non-transplant patients with lymphoproliferative disorders has never been studied to our knowledge.

PATIENTS AND METHODS

We studied, the effect of rituximab-based immunochemotherapy on the EBV status of 44 patients with leukemic low grade B-cell lymphoma.

RESULTS

After three cycles of rituximab-based treatment, only 1/17 patients was still positive for EBV.

DISCUSSION

Our results suggest that rituximab used in the treatment of EBV-positive low-grade lymphoma is efficient in eradicating the virus from the peripheral blood, a fact with potential implications in the course and prognosis of the disease.

摘要

背景

B 淋巴细胞感染 EBV 后，病毒基因组仍存在于细胞核内，并建立潜伏期，在此期间只有少数病毒基因表达。其中，LMP1 对转化至关重要。利妥昔单抗是一种用于治疗低度 B 细胞淋巴瘤的有效药物，也广泛用于治疗由 EBV 引起的移植后淋巴组织增生性疾病。据我们所知，尚未研究利妥昔单抗治疗对非移植患者淋巴组织增生性疾病中潜伏 EBV 感染的影响。